240 related articles for article (PubMed ID: 10981292)
21. [Treatment of small cell lung cancer].
Negoro S
Gan To Kagaku Ryoho; 2005 Jun; 32(6):777-82. PubMed ID: 15984515
[TBL] [Abstract][Full Text] [Related]
22. Irinotecan plus cisplatin in small-cell lung cancer.
Sandler A
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):39-43. PubMed ID: 12375800
[TBL] [Abstract][Full Text] [Related]
23. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
Johnson FM; Krug LM; Tran HT; Shoaf S; Prieto VG; Tamboli P; Peeples B; Patel J; Glisson BS
Cancer; 2006 Jan; 106(2):366-74. PubMed ID: 16342249
[TBL] [Abstract][Full Text] [Related]
24. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang L; Huang R; Chu Z; Zhan Q
J Thorac Oncol; 2010 Jun; 5(6):867-73. PubMed ID: 20521354
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan in small-cell lung cancer: the US experience.
Sandler AB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):11-2. PubMed ID: 11221015
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
Bae SH; Ryoo HM; Do YR; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Lee WS; Hur IK; Baek JH; Park KU
Lung Cancer; 2008 Jan; 59(1):76-80. PubMed ID: 17767977
[TBL] [Abstract][Full Text] [Related]
27. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):17-21. PubMed ID: 12886869
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Lara PN; Gandara DR; Natale RB
Clin Lung Cancer; 2006 Mar; 7(5):353-6. PubMed ID: 16640809
[No Abstract] [Full Text] [Related]
29. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.
Lara PN; Chansky K; Shibata T; Fukuda H; Tamura T; Crowley J; Redman MW; Natale R; Saijo N; Gandara DR
Cancer; 2010 Dec; 116(24):5710-5. PubMed ID: 20737417
[TBL] [Abstract][Full Text] [Related]
30. [Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Couteau C; Armand JP
Bull Cancer; 1998 Dec; Spec No():47-50. PubMed ID: 9932085
[TBL] [Abstract][Full Text] [Related]
31. Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Natale RB
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):22-6. PubMed ID: 12886870
[TBL] [Abstract][Full Text] [Related]
32. [Chemotherapy for lung cancer patients].
Uramoto H; Kagami S; Iwashige A; Tsukada J
J UOEH; 2006 Mar; 28(1):75-84. PubMed ID: 16541742
[TBL] [Abstract][Full Text] [Related]
33. Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.
Green MR; Dowlati A; Yellamraju L; Daniels L; Willey J; Andrews M; Leff R
J Thorac Oncol; 2007 Oct; 2(10):953-6. PubMed ID: 17909359
[TBL] [Abstract][Full Text] [Related]
34. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).
Sekine I; Nishiwaki Y; Noda K; Kudoh S; Fukuoka M; Mori K; Negoro S; Yokoyama A; Matsui K; Ohsaki Y; Nakano T; Saijo N;
Ann Oncol; 2003 May; 14(5):709-14. PubMed ID: 12702524
[TBL] [Abstract][Full Text] [Related]
36. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
Bunn PA
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-153-S12-162. PubMed ID: 9331142
[TBL] [Abstract][Full Text] [Related]
37. Topoisomerase I targeting agents in small-cell lung cancer.
Ohe Y; Saijo N
Curr Oncol Rep; 2001 Mar; 3(2):170-8. PubMed ID: 11177750
[TBL] [Abstract][Full Text] [Related]
38. [Combination of irinotecan hydrochloride and etoposide for treatment of refractory or relapsed small-cell lung cancer].
Negoro S; Masuda N
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1105-8. PubMed ID: 10945003
[TBL] [Abstract][Full Text] [Related]
39. Combined chemoradiation therapy for limited-stage small-cell lung cancer.
Teng M; Choy H; Ettinger D
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):107-15. PubMed ID: 10550834
[TBL] [Abstract][Full Text] [Related]
40. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
